Roflumilast Altana Pharma.
Roflumilast is a specific PDE4 inhibitor being developed by Altana Pharma (formerly known as Byk Gulden) for the potential treatment of asthma and chronic obstructive pulmonary disease [312928].
Reid
Peter
P
Western General Hospital, Edinburgh, UK. Peter.Reid@luht.scot.nhs.uk
D000631:Aminopyridines / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003521:Cyclopropanes; D006801:Humans; D007962:Leukocytes / Q000187:drug effects / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000631:Aminopyridines; D018927:Anti-Asthmatic Agents; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast